Concepts to Target MYC in Pancreatic Cancer

Mol Cancer Ther. 2016 Aug;15(8):1792-8. doi: 10.1158/1535-7163.MCT-16-0050. Epub 2016 Jul 12.

Abstract

Current data suggest that MYC is an important signaling hub and driver in pancreatic ductal adenocarcinoma (PDAC), a tumor entity with a strikingly poor prognosis. No targeted therapies with a meaningful clinical impact were successfully developed against PDAC so far. This points to the need to establish novel concepts targeting the relevant drivers of PDAC, like KRAS or MYC. Here, we discuss recent developments of direct or indirect MYC inhibitors and their potential mode of action in PDAC. Mol Cancer Ther; 15(8); 1792-8. ©2016 AACR.

Publication types

  • Review
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Antineoplastic Agents / pharmacology
  • Antineoplastic Agents / therapeutic use
  • Carcinoma, Pancreatic Ductal / drug therapy
  • Carcinoma, Pancreatic Ductal / genetics
  • Carcinoma, Pancreatic Ductal / metabolism
  • Carrier Proteins
  • Gene Expression Regulation, Neoplastic / drug effects
  • Gene Regulatory Networks
  • Genetic Variation
  • Humans
  • Molecular Targeted Therapy
  • Pancreatic Neoplasms / drug therapy
  • Pancreatic Neoplasms / genetics*
  • Pancreatic Neoplasms / metabolism*
  • Protein Binding
  • Protein Kinase Inhibitors / pharmacology
  • Protein Kinase Inhibitors / therapeutic use
  • Proto-Oncogene Proteins c-myc / antagonists & inhibitors
  • Proto-Oncogene Proteins c-myc / genetics*
  • Proto-Oncogene Proteins c-myc / metabolism*
  • Signal Transduction / drug effects

Substances

  • Antineoplastic Agents
  • Carrier Proteins
  • Protein Kinase Inhibitors
  • Proto-Oncogene Proteins c-myc